Tuna Mutis

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers, Yu‐Tzu Tai, Michael S. van der Veer et al. · The Journal of Immunology · 2010 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof et al. · Blood · 2016 · 918 citations · Full text

Life Sciences, Immunology, Oncology +17

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B. Overdijk, Sandra Verploegen, Marijn Bögels et al. · mAbs · 2015 · 503 citations · Full text

Medicine, Immunology, Oncology +17

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

W. A. Erik Marijt, Mirjam H.M. Heemskerk, Freke M. Kloosterboer et al. · Proceedings of the National Academy of Sciences · 2003 · 405 citations

Medicine, Hematology, Immunology +17

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen et al. · Blood · 2016 · 380 citations · Full text

Life Sciences, Immunology, Oncology +13